

# **Translational Bioinformatics for Immunogenomics**

# Table of contents


|  |           |
|--|-----------|
| <b>Welcome</b>                                   | <b>5</b>  |
| <b>Introduction</b>                              | <b>6</b>  |
| <b>Human Leukocyte Antigens</b>                  | <b>7</b>  |
| Background . . . . .                             | 7         |
| HLA Class I . . . . .                            | 7         |
| HLA Class II . . . . .                           | 7         |
| HLA Nomenclature . . . . .                       | 7         |
| Functional Divergence . . . . .                  | 7         |
| HLA Imputation Programs . . . . .                | 8         |
| <b>Killer Cell Immunoglobulin-like Receptors</b> | <b>9</b>  |
| Background . . . . .                             | 9         |
| KIR Locus . . . . .                              | 9         |
| KIR Diversity . . . . .                          | 12        |
| NK Cell Education . . . . .                      | 13        |
| KIR Nomenclature . . . . .                       | 13        |
| Inhibitory KIR . . . . .                         | 13        |
| Activating KIR . . . . .                         | 14        |
| Broad KIR Haplotypes . . . . .                   | 14        |
| KIR Ligand Motifs . . . . .                      | 14        |
| KIR3DL1 and KIR3DS1 . . . . .                    | 15        |
| KIR Allele Imputation Programs . . . . .         | 16        |
| <b>ERAP</b>                                      | <b>17</b> |
| <b>Epistatic Interactions</b>                    | <b>18</b> |
| KIR-HLA . . . . .                                | 18        |
| <b>Bonus</b>                                     | <b>19</b> |

|  |           |
|--|-----------|
| <b>Drug Allergy</b>                            | <b>20</b> |
| Immediate Drug Allergy . . . . .               | 20        |
| Skin Testing . . . . .                         | 20        |
| Skin Prick Testing . . . . .                   | 20        |
| Intradermal Testing . . . . .                  | 20        |
| Delayed Drug Allergy . . . . .                 | 20        |
| Skin Testing . . . . .                         | 20        |
| Intradermal Testing . . . . .                  | 21        |
| Patch Testing . . . . .                        | 22        |
| Specific Drugs . . . . .                       | 23        |
| Antibiotics . . . . .                          | 23        |
| Cephalosporins . . . . .                       | 23        |
| Fluoroquinolones . . . . .                     | 23        |
| Macrolides . . . . .                           | 23        |
| Penicillins . . . . .                          | 25        |
| Sulfa Antibiotics . . . . .                    | 25        |
| Vancomycin . . . . .                           | 25        |
| Bupropion . . . . .                            | 25        |
| Iron . . . . .                                 | 25        |
| Background . . . . .                           | 25        |
| Immediate Hypersensitivity Reactions . . . . . | 26        |
| Minor Infusion Reactions . . . . .             | 26        |
| Skin Testing . . . . .                         | 27        |
| Management . . . . .                           | 27        |
| References . . . . .                           | 27        |
| Local Anesthetics . . . . .                    | 28        |
| Radiocontrast . . . . .                        | 28        |
| Background . . . . .                           | 28        |
| Infusion Reactions . . . . .                   | 28        |
| Immediate Hypersensitivity Reactions . . . . . | 28        |
| Delayed Hypersensitivity Reactions . . . . .   | 29        |
| Skin Testing . . . . .                         | 29        |
| Intravenous Challenge . . . . .                | 29        |
| Management . . . . .                           | 29        |
| <b>Genotype Imputation</b>                     | <b>30</b> |
| Michigan Imputation Server . . . . .           | 30        |
| TOPMed Imputation Server . . . . .             | 30        |
| Reference Panels . . . . .                     | 30        |
| Genome Assemblies . . . . .                    | 31        |

|  |           |
|--|-----------|
| <b>Bioinformatic Best Practices</b>          | <b>32</b> |
| Project Organization . . . . .               | 32        |
| Version Control with Git . . . . .           | 32        |
| File Naming Conventions . . . . .            | 33        |
| Application Containers with Docker . . . . . | 34        |
| <b>Presenting Your Medical Research</b>      | <b>35</b> |
| Font . . . . .                               | 35        |
| Font Size . . . . .                          | 36        |
| Word Count . . . . .                         | 36        |
| Timing . . . . .                             | 36        |
| Figures . . . . .                            | 36        |
| References . . . . .                         | 37        |
| Equipment . . . . .                          | 37        |
| Laptop . . . . .                             | 37        |
| Hub . . . . .                                | 37        |
| USB Drive . . . . .                          | 38        |
| Presentation Remote . . . . .                | 38        |
| <b>On Being a Physician-Scientist</b>        | <b>39</b> |
| Daily Writing Practice . . . . .             | 39        |
| Research on Daily Writing . . . . .          | 40        |
| Time Target for Daily Writing . . . . .      | 40        |
| Tips for Daily Writing . . . . .             | 40        |
| Benefits of Daily Writing . . . . .          | 41        |
| Academic Medicine Jobs . . . . .             | 41        |
| AAMC Faculty Salary Report . . . . .         | 41        |
| Tenure-Track Offer Letters . . . . .         | 42        |
| NIH Loan Repayment Program . . . . .         | 42        |
| Online Resources . . . . .                   | 42        |
| Edge for Scholars . . . . .                  | 42        |
| NCFDD . . . . .                              | 42        |
| Professional Organizations . . . . .         | 42        |
| Suggested Readings . . . . .                 | 42        |
| Not Discussed . . . . .                      | 42        |
| Publishing Your Medical Research . . . . .   | 43        |
| <b>References</b>                            | <b>44</b> |

# Welcome

This is the website for “Translational Bioninformatics for Immunogenomics.”



# Introduction

# Human Leukocyte Antigens

## Background

HLA is located on chromosome 6 in the Major Histocompatibility Complex (MHC).

## HLA Class I

HLA class I molecules are expressed by healthy nucleated cells.

## HLA Class II

HLA class II molecules are expressed by professional antigen-presenting cells (APC)—dendritic cells, macrophages, and B cells.

## HLA Nomenclature

## Functional Divergence

Heterozygosity of HLA class I genes is associated with better outcomes after HIV infection. This is thought to be due to a greater repertoire of HIV peptides presented and cytotoxic T cell response. However, looking at HLA class I allotype alone does not take into account differences in actual peptide repertoire. Viard et al. (2024) developed a metric to measure this difference, termed “functional divergence.” Functional divergence predicts the peptide repertoire as a continuum. They

showed that greater functional divergence was associated with better HIV outcomes. Functional divergence may be relevant to other diseases where HLA heterozygosity confers advantage, such as infection, vaccination, and immunotherapy.

You can download functional divergence estimates for pairwise combinations of HLA-A, HLA-B, and HLA-C alleles from their article's Supplementary Materials. The functional divergence measure ranges from 0 (i.e., smallest functional divergence) to 1 (i.e., greatest functional divergence).

## HLA Imputation Programs

| Name                    | Programming            |                     | Output                     | Reference           |
|-------------------------|------------------------|---------------------|----------------------------|---------------------|
|                         | Language               | Input Data          |                            |                     |
| <a href="#">SNP2HLA</a> | Command line interface | PLINK binary format | HLA class I and II alleles | Jia et al. (2013)   |
| <a href="#">HIBAG</a>   | R                      | Plink binary format | HLA class I and II alleles | Zheng et al. (2014) |



# Killer Cell Immunoglobulin-like Receptors

## Background

KIR is located on chromosome 19 (19q13.4) in the Leukocyte Receptor Complex (LRC). KIR is expressed on the surface of Natural Killer (NK) cells and some T cells. KIR do not undergo somatic rearrangement—a key difference from T-cell receptors. KIR interacts with HLA class I—their cognate ligand—to recognize and destroy unhealthy tissue cells while preventing the same from occurring to healthy cells. Therefore, NK cells play a role in fighting infections, resisting some cancers, pregnancy, and preventing autoimmunity. For further reading and references, I highly recommend the review article by Pollock, Harrison, and Norman on the immunogenetics and co-evolution of KIR and HLA class I.

## KIR Locus

Adapted from Pollock, Harrison, and Norman. JACI: In Practice. 2022.

Gene

3DL3

2DS2

2DL2/3

2DL5B

2DS3

2DL1

2DL4

3DL1

3DS1

2DL5A

2DS5

2DS4

2DS1

3DL2

Function

Inhibit.

Activ.

Inhibit.

Inhibit.

Activ.

Inhibit.

Activ.

Inhibit.

Activ.

Inhibit.

Activ.

Activ.

Activ.

Inhibit.

Alleles

228

65

98

47

71

173

112

184

39

44

88

39

33

166

Allotypes

112

22

50

21

23

65

58

92

22

19

38

20

12

115

HLA Class I Ligand Motifs

B7H7

A\*11 C1

B46:01 B73:01 C1 C2

PVR

?

C2

HLA-G

Bw4+ HLA-A and Bw4+ HLA-B

Bw4+ HLA-B and HLA-F

PVR

C2

A\*11 HLA-C

C2

A3 A11

: Adapted from *Pollock, Harrison, and Norman. JACI: In Practice. 2022.*

## KIR Diversity

KIR diversity is influenced by gene content variation and sequence variation. Distinct DNA sequences of KIR genes are called “alleles.” Distinct polypeptide sequences of KIR genes are called “allotypes.” Because different DNA sequences of KIR gene can lead to the same polypeptide, there are more alleles than allotypes for a given KIR gene.

| KIR Diversity Concept  | Definition   |
|------------------------|--|
| Gene Content Variation | Presence/absence, fusion, duplication  |
| Sequence Variation     | May alter ligand affinity or specificity, signal transduction ability, or surface expression (e.g., promoter activity, translation, intracellular trafficking) |
| Allele                 | Distinct DNA sequence  |
| Allotype               | Distinct polypeptide sequence  |

## NK Cell Education

| NK Cell Education<br>(i.e., Arming, Licensing) | Corresponding Pairs of KIR and HLA Class I Ligands | Cytotoxicity and other Effector Abilities |
|--|--|---|
| Strong   | Many   | More                                      |
| Weak   | Few  | Less                                      |

## KIR Nomenclature

### Inhibitory KIR

The main role of inhibitory KIR is to prevent cytotoxic NK and T cells from killing tissue cells—unless their HLA class I expression is lost or altered by infection or mutagenesis.

## Activating KIR

Activating KIR help identify diseased cells for destruction by cytotoxic NK and T cells. Binding of foreign peptides by HLA class I molecules retained by infected cells may be most critical for activating KIR.

## Broad KIR Haplotypes

| Broad KIR Haplotype | KIR Copy Number Variation | KIR Gene Organization  | Activating KIR |
|---------------------|---------------------------|------------------------|----------------|
| A                   | Relatively stable         | Generally non-variable | Less           |
| B                   | Extensive                 | Highly variable        | More           |

## KIR Ligand Motifs

Table 0.4: Adapted from *Pollock, Harrison, and Norman. JACI: In Practice. 2022.*

| KIR Ligand Motif | HLA-A Allotypes | HLA-B Allotypes | HLA-C Allotypes |
|------------------|-----------------|-----------------|-----------------|
| A3/A11A*03, A*11 | _____           | _____           | _____           |



same gene. Of the KIR3DS1 allotypes—3DS1013 and 014—are observed with the greatest frequency in any population.

## KIR Allele Imputation Programs

| Name                    | Programming Language | Input Data           | Output  | Reference                      |
|-------------------------|----------------------|----------------------|---|--------------------------------|
| <a href="#">PONG</a>    | R                    | PLINK bi-nary format | KIR3DL1/S1 alleles (Global Model includes 51 alleles)   | <a href="#">Harrison, 2022</a> |
| <a href="#">KIR*IMP</a> | Online portal        | HAPS/IMPT format     | ISAMPLE types: 17 loci (presence/absence and copy number) plus 2 extended haplotype classifications ( A and B haplotypes) | <a href="#">Vukcevic, 2015</a> |



# ERAP

ERAP is located on chromosome 5.

# Epistatic Interactions

## KIR-HLA

Epistatic interactions between KIR and HLA are associated with ankylosing spondylitis ([Hanson, 2020](#))

## Bonus

# Drug Allergy

## Immediate Drug Allergy

### Skin Testing

Concentrations typically employed for drug skin testing are 1:10, 1:100, and full strength.

### Skin Prick Testing

### Intradermal Testing

## Delayed Drug Allergy

### Skin Testing

Table 0.1: Utility of patch and intradermal skin testing for delayed drug allergy reaction types

| Reaction  | Patch Testing                                      | Intradermal Testing                                       |
|---|--|---|
| Maculopapular exanthem (MPE)                                  | Useful if positive                                 | Useful if positive  |
| Acute generalized exanthematous pustulosis (AGEP)             | Useful if positive                                 | Useful if positive  |
| Stevens-Johnson Syndrome/Toxic epidermal necrolysis (SJS/TEN) | Low sensitivity but potentially useful if positive | Contraindicated due to concern for potential reactivation |

| Reaction  | Patch Testing                             | Intradermal Testing |
|---|---|---------------------|
| Drug reaction with eosinophilia and systemic symptoms (DRESS) | Useful if positive                        | Useful if positive  |
| Fixed drug eruption   | Useful if applied to the site of reaction | Not useful          |
| Drug-induced organ injury (e.g., kidney, liver)               | Not useful                                | Not useful          |

### ! Important

No delayed skin testing method has 100% negative predictive value.

Table 0.2: Shared characteristics of patch and intradermal testing

| Characteristic          | Details   |
|-------------------------|---|
| Timing                  | Perform at least 6 to 8 weeks after reaction; and 6 months or later after DRESS   |
| Concomitant medications | Most medications okay to continue, including anti-histamines and beta-blockers. Should be off of steroids for 1 month or prednisone equivalent dose 10 mg/day |

## Intradermal Testing

Table 0.3: Characteristics of intradermal testing

| Characteristic   | Details   |
|------------------|---|
| Testing site     | Volar forearm or extensor upper arm   |
| Testing reagents | Must be sterile; often higher concentrations than those used for immediate skin testing |

| Characteristic Details |                                |
|------------------------|--------------------------------|
| Reading                | At 24 hours                    |
| Controls               | + None<br>- Saline             |
| Test interpretation    | + Papule present<br>- Negative |

## Patch Testing

Table 0.4: Characteristics of patch testing

| Characteristic                 | Details  |
|--------------------------------|--|
| Testing site                   | Back or upper arm (needs to be hairless)   |
| Testing reagents               | 1% and 10% of reagent grade product; 10% and 30% of trade product; most commonly used vehicle is petrolatum  |
| Controls                       | + None<br>- Petrolatum   |
| Shelf-life of patch test mixes | Most antibiotics at room temperature are stable for 1 to 3 months; check with USP Pharmacopeia for verification  |
| Patches                        | Finn chambers (can be aluminum or molded plastic)  |
| Tape                           | Use hypoallergenic paper tape  |
| Reading                        | At 48 hours (85% of drugs-if will be positive-are positive by this point); 72 hours; 96 hours; and 1 week  |
| Test interpretation            | - Negative<br>? Doubtful reaction<br>+ Weak reaction, erythema<br>++ Strong reaction, erythema, papules, or vesicles<br>+++ Extreme, bullous, ulcerative |

## Specific Drugs

### Antibiotics

#### Cephalosporins

#### Fluoroquinolones

#### Macrolides

### Background

#### What is the chemical structure of macrolides?

Macrolides are defined by a large lactone ring, which varies from 12 to 16 carbons, with 1 or more attached sugar chains. Erythromycin and clarithromycin have 14 carbons in their lactone rings while azithromycin has 15.

#### What is the mechanism of action of macrolides?

As 50S ribosomal subunit inhibitors, macrolides exert their bacteriostatic effect by inhibiting protein synthesis.

#### What is the cross-reactivity pattern macrolide antibiotics?

While not extensively studied, macrolide antibiotics with a different number of carbon atoms in their lactone ring are tolerated by most patients. Macrolide antibiotics are also unlikely to cross-react with macrolide immunosuppressants (e.g., tacrolimus, sirolimus).

#### What are some infections that use macrolides as first-line therapy?

Clarithromycin is used as part of combination treatment for *H. pylori*. Azithromycin is a part of the first-line combination therapy for *Mycobacterium avium* complex.

## **Non-Hypersensitivity Reactions**

### **GI Side Effects**

Because macrolides are also agonists for the motilin receptor—stimulating gastric and small intestine motility—they can cause nausea, vomiting, diarrhea, and abdominal cramping. Accordingly, erythromycin can be used as a treatment for gastroparesis.

### **Sensorineural Ototoxicity**

Macrolides can cause usually, transient sensorineural ototoxicity.

### **QT Interval Prolongation**

Macrolides are associated with QT interval prolongation.

### **Skin Testing**

Skin testing for macrolide immediate hypersensitivity has not been shown to be reliable.

### **Oral Challenge**

For patients with a history of immediate hypersensitivity reaction to a macrolide, graded azithromycin challenge can be performed, starting with azithromycin 25 mg followed by 1 hour observation then 250 mg followed by 2 hour observation.

For patients with a history of non-severe delayed hypersensitivity reaction to a macrolide, single dose azithromycin 250 mg challenge with 2 hour observation can be performed. Patients should be instructed to report any other delayed symptoms, which may occur up to 24 to 48 hours after the challenge dose.



## Penicillins

## Sulfa Antibiotics

## Vancomycin

## Bupropion

## Iron

## Background

### Why is intravenous (IV) iron used?

IV iron is used for the treatment of iron deficiency anemia when oral iron is effective or not tolerated.

### What IV iron formulations are available in the United States?

Formulations available in the United States include low-molecular-weight iron dextran (LWMID), ferric gluconate, iron sucrose, ferumoxytol, iron isomaltoside, and ferric carboxymaltose.

#### Note

High-molecular weight iron dextrans were discontinued in the United States due to having a higher rate of hypersensitivity reactions.

Table 0.5: Characteristics of iron formulations available in the United States

| Generic name          | Iron gluconate | Iron Sucrose | Low-molecular-weight iron dextran (LWMID) | Ferric carboxymaltose | Iron isomaltoside | Ferumoxytol |
|-----------------------|----------------|--------------|---|-----------------------|-------------------|-------------|
| Brand name            | Ferrlecit      | Venofer      | INFeD                                     | Injectafer            | Monofer           | FeraHeme    |
| Molecular weight (kD) | 289-440        | 30-60        | 165                                       | 150                   | 150               | 750         |

| Generic name                  | Iron gluconate | Iron Sucrose | LMW Dextran | Ferric carboxymaltose | Iron isomaltoside | Ferumoxytol |
|-------------------------------|----------------|--------------|-------------|-----------------------|-------------------|-------------|
| Labile iron (% injected dose) | 3.3            | 3.5          | 2           | 0.6                   | 1                 | 0.8         |

## Immediate Hypersensitivity Reactions

### What is the incidence of anaphylactic reactions with IV iron?

Anaphylactic reactions—when high-molecular weight dextrans are excluded—occur with an incidence of < 1 in 200,000.

Significant differences in reaction risk have not been shown among low-molecular weight iron dextran, iron sucrose, ferric gluconate, and ferric carboxymaltose.

### What is mechanism of most IV iron immediate hypersensitivity reactions?

Most IV iron immediate hypersensitivity reactions are mediated through complement-activation related pseudoallergy (CARPA). Rarely, hypersensitivity reactions are IgE-mediated.

## Minor Infusion Reactions

### What are the symptoms of minor infusion reactions to IV iron?

Symptoms of minor infusion reactions to IV iron include—flushing, chest/back tightness, myalgias—and, importantly, do not have any features of anaphylaxis.

### What is considered to be the main driver of minor infusion reactions to IV iron?

Labile, or also called “free,” iron is associated with minor infusion reactions to IV iron.

## **Skin Testing**

### **What is the utility of immediate skin testing for IV iron hypersensitivity reactions?**

As most hypersensitivity reactions are non-IgE-mediated—rather via CARPA—skin testing has limited utility for evaluating IV iron hypersensitivity reactions; however, it may help detect the rare patients with IgE-mediated hypersensitivity.

## **Management**

### **What are some approaches to subsequent IV iron administration in patients with previous IV iron reactions?**

Approaches for patients with history of mild to moderate IV iron reactions include: switching to an alternative IV iron formulation, slowing the infusion rate (e.g., 10% of recommended rate during the first 10 to 15 minutes), and/or pre-treatment with non-sedating, second generation antihistamines.

For patients with a history of anaphylactic reactions to IV iron, desensitization can be considered, such as ferric gluconate.

## **References**

Gómez-Ramírez S, Shander A, Spahn DR, et al. Prevention and management of acute reactions to intravenous iron in surgical patients. *Blood Transfusion*. Published online April 10, 2019. doi:[10.2450/2018.0156-18](https://doi.org/10.2450/2018.0156-18)

Muñoz M, Gómez-Ramírez S, Bhandari S. The safety of available treatment options for iron-deficiency anemia. *Expert Opin Drug Saf* 2018; 17: 149-59.

## **Local Anesthetics**

## **Radiocontrast**

### **Background**

#### **How do modern, radiocontrasts differ from older radiocontrasts?**

Modern radiocontrasts are non-ionic, iodinated and either iso-osmolal or low-osmolality. Older radiocontrasts were high-osmolality—which are no longer used intravenously.

#### **Is radiocontrast allergy related to iodine or seafood allergy?**

The radiocontrast molecular structure is responsible for hypersensitivity reactions—not iodine or seafood allergy. Shellfish allergy is secondary to tropomyosin not iodine.

### **Infusion Reactions**

These are also referred to as “toxic” or “chemotoxic” reactions. Characteristic symptoms include transient warmth/flushing, nausea/vomiting, chest pain, metallic taste, hypertension, and/or vasogal signs.

### **Immediate Hypersensitivity Reactions**

The most common immediate hypersensitivity reaction to radiocontrast is mild urticaria and pruritus, occurring in ~0.9% - 3.1% of patients receiving radiocontrast. Anaphylaxis occurs in 0.02% - 0.04% of patients. Of immediate hypersensitivity reactions, 70% occur within 5 minutes of radiocontrast injection and 96% of severe reactions occur within 20 minutes.

## **Delayed Hypersensitivity Reactions**

The most common delayed hypersensitivity reaction to radiocontrast is a maculopapular exanthem—occurring in 1 to 3% of patients.

## **Skin Testing**

Skin prick testing to the culprit and other radiocontrasts followed by intradermal testing—if skin prick testing is negative—can be useful for identifying an alternative radiocontrast agent. A skin test negative radiocontrast alternative has a 95% NPV.

## **Intravenous Challenge**

Intravenous challenge can be performed to radiocontrast with various protocols—such as 1 mL, 5 mL, 15, mL, and 50 mL (cumulative 71 mL) at 60 minute intervals.

## **Management**

The culprit radiocontrast should be avoided, and an alternative radiocontrast should be used, guided by negative skin testing if available. Other measures to decrease risk of recurrent radiocontrast reaction include: lowering the radiocontrast dose, decreasing the injection speed, and pre-treatment with non-sedating, second generation antihistamines and/or corticosteroids.

# Genotype Imputation

## Michigan Imputation Server

The [Michigan Imputation Server](#) is a free next-generation genotype imputation platform. You can learn more about the Michigan Imputation Server by visiting their [Getting Started](#) documentation. The [1000 Genomes Phase 3 \(Version 5\)](#) Reference Panel is available on the Michigan Imputation Server.

## TOPMed Imputation Server

The [TOPMed Imputation Server](#) is another free next-generation genotype imputation platform developed by the [University of Michigan](#) and powered by data from the [TOPMed Program](#) investigators. You can learn more about the TOPMed Imputation Server by visiting their [Getting Started](#) documentation. The [TOPMed Version 3](#) Reference Panel was released in December 2023.

## Reference Panels

| Reference Panel                                  | Genome             |   | Chr. Imputation Server                     |
|--|--------------------|---|--|
|  | As-<br>sem-<br>bly | No. of Sites<br>Sam- (chr1-<br>ples 22) |  |
| <a href="#">1000 Genomes Phase 3 (Version 5)</a> | GRCh37             | 27,041,149,143,160,522, X               | <a href="#">Michigan Imputation Server</a> |

| Reference Panel                       | Genome             |                              |   | Chr. Imputation Server |
|---------------------------------------|--------------------|------------------------------|---|------------------------|
|                                       | As-<br>sem-<br>bly | No. of Sites<br>Sam-<br>ples | (chr1-<br>22)                               |                        |
| <a href="#">TOPMed</a><br>(Version 3) | GRCh38             | 15,974,600,182               | <a href="#">TOPMed</a><br>Imputation Server | X                      |

## Genome Assemblies

The [Genome Reference Consortium](#) (GRC) is the main source of human genome assembly data. The most recent human genome assembly version is GRCh38, released in 2013. The “h” in “GRCh” stands for “human.” The GRC also maintains genome assembly data for rat (r), mouse (m), zebrafish (z), and chicken (g for gallus). Major updates, called “versions”, are released every few years. Minor updates are called “patches” and are released more frequently.

GRCh38 is referred to as “hg38” in the [University of California Santa Cruz \(UCSC\) Genome Browser](#). The “hg” stands for “human genome.” Before the GRCh38 genome assembly, the version numbers of the GRC and UCSC Genome Browser genome assemblies did not match. For example, when the GRCh37 genome assembly was released in 2009, the UCSC Genome Browser version was “hg19.” Therefore, to minimize confusion, starting with the GRCh38 genome assembly, the [UCSC Genome Browser](#) version number was matched as “hg38.”

| GRC<br>Version | UCSC<br>Version | Year Re-<br>leased | Genome<br>Coverage | Alternate<br>Haplotypes                |
|----------------|-----------------|--------------------|--------------------|--|
| GRCh37         | hg19            | 2009               | ~92.5%             | 3 regions with 9<br>alternate loci     |
| GRCh38         | hg38            | 2013               | 95%                | 178 regions with 261<br>alternate loci |

# Bioinformatic Best Practices

I recommend the tutorial, “A Reproducible Data Analysis Workflow With R Markdown, Git, Make, and Docker” as a starting point for R-based data analyses ([Peikert & Brandmaier, 2021](#)).

## Project Organization

### Bash Commands to Create Folder Directory Structure for Your R Project

```
cd </path/to/parent/directory>
mkdir <your-r-project-folder>
cd <your-r-project-folder>
touch README.md
mkdir data doc src bin outputs
```

Once you have downloaded your raw data to your data folder, you should make the contents of the data folder read-only (non-editable) with the following command: `chmod u-w -R data/`

## Version Control with Git

I recommend the [Using Git and GitHub with RStudio Cheat-sheet](#) for additional helpful commands.

### Verify Git Installation and Version

```
which git # request path to your Git executable
git --version # check your Git version
```



## Introduce Yourself to Git

```
git config --global user.name "<username>"
git config --global user.email "<email>"
```

## Create a New Repository on GitHub

Go to GitHub to create your new repository, then initialize your repository from the command line.

```
cd </path/to/your-r-project-folder>
echo "# your-r-project-folder" >> README.md
git init
git add README.md
git commit -m "first commit"
git branch -M main
git remote add origin https://github.com/<user.name>/<your-repository>.git
git push -u origin main
```

## Add, Commit, and Push Files to Remote Repository

```
git add <file-name>
git commit -m "description"
git push
```

## File Naming Conventions

In your README.md, you should define naming conventions for your project files. The main elements for a file naming convention are metadata, separator, and version tracking. I recommend the [File Naming Conventions Worksheet](#) (Briney, 2020) to develop your file naming conventions.

| Metadata  | Separator   | Version Tracking                                     |
|---|---|--|
| 3 to 5 pieces max<br>(e.g. sample ID, date in ISO 8601 format such as YYYY-MM-DD) | Dashes (-), underscore (_), or camel case (i.e., capitalize each word without spaces) | Numeric (e.g., v01) or Status (e.g., raw, processed) |

#### Example

My naming convention for R Markdown analysis files is: “analysis-YYYY-MM-DD-version.Rmd” where version starts with “v01.” This is my first analysis file, “analysis-YYYY-MM-DD-v01.Rmd”

## Application Containers with Docker

# Presenting Your Medical Research

## Font

You should use a [sans-serif](#) font like Arial to maximize readability. “Serifs” are extending features at the end of letters. Times New Roman is a serif font.

Table 0.1: Sans-serif versus serif fonts<sup>1</sup>

| Font                    | Illustration   | Examples                                       |
|-------------------------|--|--|
| Sans-serif font         |   | Arial,<br>Calibri,<br>Helvetica                |
| Serif font              |  | Times<br>New<br>Roman,<br>Georgia,<br>Garamond |
| Serifs (colored in red) |  |  |

## Font Size

| Slide Section                               | Font Size |
|---|-----------|
| Title                                       | 36 – 44   |
| Text<br>(e.g., Bullets, Figures,<br>Tables) | 24 – 28   |
| References                                  | 20 – 24   |

## Word Count

The fewer words, the better. A rule to follow is the [7×7 rule](#): no more than 7 lines and no more than 7 words per line.

## Timing

You should estimate approximately 1 minute per slide.

## Figures

I recommend creating your figures as [Scalable Vector Graphics](#) (SVG). The main advantages of the SVG format include always maintaining its resolution and smaller file size than pixel-based image formats (e.g., JPEG).

Some tools that you can use to get started creating SVG include [Microsoft PowerPoint](#) (subscription), [Adobe Illustrator](#) (subscription), [draw.io](#) (free), and [Inkscape](#) (free). [Draw.io](#) is best for diagrams and flowcharts. [Inkscape](#) is better for flexible drawings. Both [draw.io](#) and [Inkscape](#) are integrated with [Bioicons](#), an open-source extension which includes >1700 icons for scientific illustrations.

---

<sup>1</sup>Font images are recreated by User:Stannered, original by en:User:Chmod007 - en:Image:Serif and sans-serif 01.png, CC BY-SA 3.0, <https://commons.wikimedia.org/w/index.php?curid=2058303>

In Microsoft PowerPoint, you can create an SVG file by selecting all shapes, right-clicking, choosing “Save as Picture”, and then picking “SVG” as the “Save as Type.”

## References

Cite references at the bottom of your slides as you present information.

 Format

Last Name. *Journal Abbreviation*. Year.

## Equipment

### Laptop

Bring your own laptop to presentations in case there isn’t a desktop computer for you to use, or it is not functioning, reliable or frustratingly slow.

### Hub

What is worse than not being able to connect your laptop to the correct cable? While a good host for a presentation should have a hub (or dongle if that’s your preferred terminology), you can come prepared with your own too—particularly important if you have a laptop with only USB-C ports and no HDMI port.

There are lots of options for hubs. If you are looking for a recommendation, I’ve found that [Anker](#) usually has a selection of high-quality and affordable hubs.

## USB Drive

Do you want the entire audience to see your most recent emails when you login to download the PowerPoint you emailed yourself? No. Me either. To avoid this, bring your presentation loaded onto a USB drive, which should ideally have both USB-A and USB-C ports. Or, you can also avoid this by using your own laptop—where the presentation should already be downloaded.

## Presentation Remote

I don't feel as strongly about bringing your own presentation remote as your own laptop, hub, and USB drive—but I think it is another piece of equipment to consider. This helps keep you from being tethered to and white knuckling the podium during your talk.

One option to consider is the [Logitech Spotlight Presentation Remote](#)—which includes features such as magnification, vibration alerts for time management (e.g., 5 minutes left), 3 hours use from 1 minute of charging, and connection by USB receiver or Bluetooth—in addition to slide advancement.

# On Being a Physician-Scientist

## Daily Writing Practice

Why is it that the most important academic activity for tenure, promotion, and professional reputation—writing—has the least amount of built-in accountability?

If you are a physician-scientist, you are a writer; therefore, you should write everyday (Monday - Friday).

Table 0.1: Built-in accountability and importance for tenure, promotion, and professional reputation by activity

| <i>Less</i>  | <b>Built-in accountability</b>   | <i>More</i>   |
|--|--|---|
| <ul style="list-style-type: none"><li>• Writing</li></ul>  | <b>-&gt;<br/>Activity</b>  | <ul style="list-style-type: none"><li>• Service</li></ul>         |
| <ul style="list-style-type: none"><li>• Articles</li></ul> | <b>&lt;-</b>   | <ul style="list-style-type: none"><li>• Teaching</li></ul>        |
| <ul style="list-style-type: none"><li>• Grants</li></ul>   | <b>Importance for tenure,<br/>promotion, and professional<br/>reputation</b> | <ul style="list-style-type: none"><li>• Clinic/Consults</li></ul> |
| <i>More</i>  |  | <i>Less</i>   |

**i** Note

The most important part of your promotion—writing—has the least accountability.

Table 0.2: Limiting beliefs to cultivating a daily writing practice. Adapted from NCFDD.

| Belief   | Reality   |
|--|---|
| “I need huge blocks of time.”                  | “ <i>Both unrealistic and untrue.</i> You can productively write in 30 minute blocks!”  |
| “I must be inspired to write.”                 | “ <i>No, you don’t.</i> If you put it on your calendar, you can show up to write just like you show up to meetings you don’t want to attend.” |
| “Writing is what I do when I’m done thinking.” | “ <i>Writing is thinking.</i> ”   |

## Research on Daily Writing

Table 0.3: Adapted from Boice (1989)

| Participant Groups                                   | Draft Pages Written per Year |
|--|------------------------------|
| No change  | 17                           |
| Wrote daily and recorded progress                    | 64                           |
| Wrote daily, recorded progress, and were accountable | 157                          |

## Time Target for Daily Writing

Your goal should be to spend 3 or more hours per week on scholarly writing. So, if you write 30 minutes Monday to Friday, you are already at 2.5 hours!

## Tips for Daily Writing

Schedule your writing in your calendar like any other meeting or clinical duty.



You should write first thing in the morning. Knock out the most important daily task for your career first!

Map complex goals to attainable steps.

Use a timer, stop when the timer goes off (to avoid slipping back into writing in huge chunks).

Leave yourself a “breadcrumb,” so you can pick up where you left off.

Give yourself a treat after writing.

Do a reflection at the end of the week (Friday) on how your writing went.

## Benefits of Daily Writing

Writing daily helps align your time with your evaluation criteria (e.g. 80% research and 20% clinical).

Table 0.4: Benefits of daily writing. Adapted from NCFDD  
{tbl-benefits-daily-writing}

| Benefit            | Description  |
|--------------------|--|
| Productivity Shift | Leads to slow, steady productivity and fewer feelings of anxiety over meeting writing expectations |
| Mental Shift       | Writing is the most important part of your success; therefore, it is your top priority.            |
| Behavior Shift     | You write everyday and find a way to be accountable that works for you!                            |

## Academic Medicine Jobs

### AAMC Faculty Salary Report

Looking to get an idea of academic faculty salaries? The annual [AAMC Faculty Salary Report](#) compiles academic faculty salaries by rank, degree, department/specialty, medical school

type, region, and more. This is often available for free through your university library. Get to know your librarian!

## **Tenure-Track Offer Letters**

What goes into a tenure-track offer letter? The [Burroughs Wellcome Fund](#) provides a comprehensive list of offer letter components in their article, “[Academic Tenure-Track Offer Letters](#).”

## **NIH Loan Repayment Program**

[NIH Loan Repayment Program](#)

## **Online Resources**

### **Edge for Scholars**

[Edge for Scholars](#)

### **NCFDD**

[NCFDD](#)

## **Professional Organizations**

[American Physician Scientists Association](#)

## **Suggested Readings**

### **Not Discussed**

[Not Discussed](#) by Michael Stein

## **Publishing Your Medical Research**

[Publishing Your Medical Research](#) by Daniel W. Byrne

## References

- Boice, Robert. 1989. “Procrastination, Busyness and Bingeing.” *Behaviour Research and Therapy* 27 (6): 605–11. [https://doi.org/https://doi.org/10.1016/0005-7967\(89\)90144-7](https://doi.org/https://doi.org/10.1016/0005-7967(89)90144-7).
- Jia, Xiaoming, Buhm Han, Suna Onengut-Gumuscu, Wei-Min Chen, Patrick J. Concannon, Stephen S. Rich, Soumya Raychaudhuri, and Paul I. W. De Bakker. 2013. “Imputing Amino Acid Polymorphisms in Human Leukocyte Antigens.” Edited by Jianming Tang. *PLoS ONE* 8 (6): e64683. <https://doi.org/10.1371/journal.pone.0064683>.
- Viard, Mathias, Colm O’hUigin, Yuko Yuki, Arman A. Bashirova, David R. Collins, Jonathan M. Urbach, Steven Wolinsky, et al. 2024. “Impact of HLA Class I Functional Divergence on HIV Control.” *Science* 383 (6680): 319–25. <https://doi.org/10.1126/science.adk0777>.
- Zheng, X, J Shen, C Cox, J C Wakefield, M G Ehm, M R Nelson, and B S Weir. 2014. “HIBAG—HLA Genotype Imputation with Attribute Bagging.” *The Pharmacogenomics Journal* 14 (2): 192–200. <https://doi.org/10.1038/tpj.2013.18>.